Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Pradaxa 110 mg, hard capsules - HSA Drug Approval Details

Approvals/HSA/Pradaxa 110 mg, hard capsules

Approved

STANDARD

Pradaxa 110 mg, hard capsules

Unknown🇸🇬 Health Sciences Authority

Approval Date: Jan 13, 2026
Approval ID: f03931257b850c6c
Company: Unknown
Type: Standard

Approval Details

Approval Id: f03931257b850c6c
Drug Name: Pradaxa 110 mg, hard capsules

Active Ingredients

DABIGATRAN ETEXILATE MESILATE 126.83 mg EQV DABIGATRAN ETEXILATE

110 mg

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jan 13, 2026

Approval ID

f03931257b850c6c

Type

Standard

Back to HSA Approvals